Expert Perspectives on the Treatment of Advanced Clear Cell Renal Cell Carcinoma

A panel of expert genitourinary oncologists give an overview of renal cell carcinoma and present the case of a 61-year-old man with metastatic clear cell RCC.

Expert oncologists give an overview of molecular testing, risk stratification, and treatment guidelines for renal cell carcinoma.

A panel of experts on renal cell carcinoma review updated data on IO-TKI regimens in advanced RCC, including the CheckMate 9ER, KEYNOTE-526, and CLEAR trials.

A comprehensive discussion on how to select the appropriate IO-TKI regimen in the frontline setting in advanced renal cell carcinoma.

Experts on renal cell carcinoma discuss frontline treatment options for favorable-risk disease and factors that impact treatment decisions.

Detailed insights on how the choice of tyrosine kinase inhibitors (TKIs) in IO-TKI regimens impact the treatment of advanced renal cell carcinoma.

RCC experts discuss second-line therapy options following progression on first-line IO-TKI regimen.

A panel of experts in renal cell carcinoma present the case of a 59-year-old woman with renal cell carcinoma and discuss systemic therapy options.

Multidisciplinary experts discuss the role of concurrent radiation in the treatment of renal cell carcinoma.

Expert oncologists review data updates on IO-IO regimens in the treatment of advanced RCC, including CheckMate 214, and discuss treatment selection among IO-IO and IO-TKI combinations.

An overview of adverse event and toxicity considerations with TKI therapies in renal cell carcinoma.

Expert oncologists discuss the management of immune-related adverse events in renal cell carcinoma.

A panel of experts on renal cell carcinoma discuss triplet therapy and review COSMIC-313, a study of cabozantinib, nivolumab, and ipilimumab in the first line.

Expert genitourinary oncologists close their discussion with advice to community oncologists treating renal cell carcinoma.